A Case Series & Review of Literature of Angiomyolipoma with Medical & Surgical Perspective.

The angiomyolipoma of renal origin is a rare benign tumour composed of fat cells, smooth muscle cells, and thick-wall blood vessels. Mostly these are sporadic origin, asymptomatic and benign in nature. Here we present two cases of Renal angiomyolipoma (AML) presenting as fever, pain, perirenal haematoma & frank haematuria. After initial stabilization, evaluated by contrast enhanced computer tomography (CECT) & diagnosed as renal angiomyolipoma because of low Hounsfield areas (10-20HU) suggestive for fat. Patient later underwent angiography with selective angioembolisation. Post intervention period was uneventful and was treated by an oral Everolimus 10 mg daily for a period of one year in first case & partial resection was done in second case. On two year follow-up both patients were doing well & had normal renal function without any recurrence. Embolisation is the emergency treatment of choice for bleeding angiomyolipoma. When preventive treatment is considered a nephron sparing approach by either transarterial embolisation or partial nephrectomy is clearly important. While angiomyolipoma in both kidneys or in solitary functioning kidneys, renal preservation is mandatory in order to avoid need for renal replacement therapy. Also, recently approved drug Everolimus may be considered for patients not suitable for surgery particularly in tumour seen with tuberous sclerosis.

[1]  Santosh Kumar,et al.  Rare Adrenal Gland Emergencies: A Case Series of Giant Myelolipoma Presenting With Massive Hemorrhage and Abscess , 2015, Nephro-urology monthly.

[2]  David Chen,et al.  Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[3]  Wen‐Pin Chen,et al.  Urgent angioembolization with early elective nephron-sparing surgery for spontaneously ruptured renal angiomyolipoma. , 2009, Journal of the Chinese Medical Association : JCMA.

[4]  C. Chuang,et al.  Embolization of Renal Angiomyolipomas: Short-Term and Long-Term Outcomes, Complications, and Tumor Shrinkage , 2009, CardioVascular and Interventional Radiology.

[5]  A. Folpe,et al.  Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. , 2007, Human pathology.

[6]  S. Sparagana,et al.  Diagnosis of Tuberous Sclerosis Complex , 2004, Journal of child neurology.

[7]  Hongbing Zhang,et al.  Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma , 2003, The Lancet.

[8]  M. Sanda,et al.  Contemporary diagnosis and management of renal angiomyolipoma. , 2002, The Journal of urology.

[9]  B. Scheithauer,et al.  Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band l6p13 occurs in sporadic as well as TSC‐associated renal angiomyolipomas , 1995, Genes, chromosomes & cancer.